Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 268

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial

Open access
Poole, Jeanne E., Bahnson, Tristram D., Monahan, Kristi H., Johnson, George, Rostami, Hoss, Silverstein, Adam P., Al-Khalidi, Hussein R., Rosenberg, Yves, Mark, Daniel B., Lee, Kerry L., Packer, Douglas L., Poole, Jeanne E., Akoum, Nazem, Aoukar, Pierre, Birgersdotter-Green, Ulrika, Blatt, Joseph, Cha, Yong Mei, Chung, Mina, Gleva, Marye, Glotzer, Taya, Henrickson, Charles, Kron, Jack, Kuriachan, Vikas, Mulpuru, Siva, Noseworthy, Peter, Patton, Kris, Prutkin, Jordan, Ranjan, Ravi, Rho, Robert, Russo, Andrea, Stecker, Eric, Tzou, Wendy, Serdoz, Laura Vitali, Wilson, Mauri · 2020 · Journal of the American College of Cardiology

Abstract

Background: CABANA randomized 2204 patients with atrial fibrillation (AF) to catheter ablation or drug therapy. Analysis by intention-to-treat (ITT), showed a non-significant 14% relative reduction in the primary outcome of death, disabling stroke, serious bleeding, or cardiac arrest. Objective: To assess recurrence of atrial fibrillation (AF) in The Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Methods: We prospectively studied CABANA patients using a proprietary ECG recording monitor for symptom-activated and 24-hour AF auto detection. The AF recurrence endpoint was any post 90-day blanking atrial tachyarrhythmias lasting 30 seconds or longer. Ninety-six-hour Holter monitoring obtained biannually was used to assess AF burden. Patients using the CABANA monitors and provided 90-day post-blanking recordings qualified for this analysis (1240, 56% of CABANA population). Treatment comparisons were performed using a modified- ITT approach. Results: Median age of the 1240 patients was 68 years, 34.4% women, and AF was paroxysmal in 43.0%. Over 60 months of follow-up, first recurrence of any symptomatic or asymptomatic AF (hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.45, 0.60, P<0.001) or, first symptomatic-only AF (HR 0.49, 95% CI 0.39, 0.61, P<0.001) were both significantly reduced in the catheter ablation group. Baseline Holter AF burden in both treatment groups was 48%. At 12 months, AF burden in ablation patients averaged 6.3%, and in drug therapy patients, 14.4%. AF burden was significantly less in catheter ablation compared with drug therapy patients across the 5-year follow-up (P <0.001). These findings were not sensitive to the baseline pattern of AF. Conclusions: Catheter ablation was effective in reducing recurrence of any AF by 48% and symptomatic AF by 51% as compared to drug therapy over 5 years of follow-up. Furthermore, AF burden was also significantly reduced in catheter ablation patients, regardless of their baseline AF type.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.04.065

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 268

Metadata

Authors
Poole, J. E., Bahnson, T. D., Monahan, K. H., Johnson, G., Rostami, H., Silverstein, A. P., Al-Khalidi, H. R., Rosenberg, Y., Mark, D. B., Lee, K. L., Packer, D. L., Poole, J. E., Akoum, N., Aoukar, P., Birgersdotter-Green, U., Blatt, J., Cha, Y. M., Chung, M., Gleva, M., Glotzer, T., Henrickson, C., Kron, J., Kuriachan, V., Mulpuru, S., Noseworthy, P., Patton, K., Prutkin, J., Ranjan, R., Rho, R., Russo, A., Stecker, E., Tzou, W., Serdoz, L. V., & Wilson, M.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2020-06
Volume
75
Issue
25
Pages
3105-3118
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3036182639
Cited by
268
References
30
FWCI
17.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. https://app.cochat.ai/papers/10.1016/j.jacc.2020.04.065
The paper
Poole, J. E., Bahnson, T. D., Monahan, K. H., Johnson, G., Rostami, H., Silverstein, A. P., Al-Khalidi, H. R., Rosenberg, Y., Mark, D. B., Lee, K. L., Packer, D. L., Poole, J. E., Akoum, N., Aoukar, P., Birgersdotter-Green, U., Blatt, J., Cha, Y. M., Chung, M., Gleva, M., . . . Wilson, M. (2020). Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2020.04.065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.